TREA

98040253 - EVOMYO

Follow

Information

  • Trademark
  • 98040253
  • Serial Number
    98040253
  • Filing Date
    June 13, 2023
    3 years ago
  • Transaction Date
    July 11, 2025
    a year ago
  • Status Date
    July 09, 2025
    a year ago
  • Published for Opposition Date
    May 21, 2024
    2 years ago
  • Location Date
    July 16, 2024
    2 years ago
  • Status Code
    731
  • Current Location
    INTENT TO USE SECTION
    Employee Name
    CHANG, BETTY
  • Attorney Name
    Maury M. Tepper, III
    Law Office Assigned Location Code
    M60
  • Owners
Information
Mark Drawing Code
4
Mark Identification
EVOMYO
Case File Statements
  • GS0051: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs being pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Case File Event Statements
  • 4/16/2024 - 2 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 4/16/2024 - 2 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/16/2024 - 2 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 6/16/2023 - 3 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 7/17/2023 - 3 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 1/31/2024 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/6/2024 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/6/2024 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/6/2024 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/17/2024 - 2 years ago
    10 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/21/2024 - 2 years ago
    13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 1/13/2025 - a year ago
    15 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 5/1/2024 - 2 years ago
    11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/21/2024 - 2 years ago
    12 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 7/16/2024 - 2 years ago
    14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 1/13/2025 - a year ago
    18 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 1/13/2025 - a year ago
    17 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 1/13/2025 - a year ago
    16 - SOU EXTENSION 1 FILED Type: EXT1
  • 7/9/2025 - a year ago
    19 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 7/9/2025 - a year ago
    20 - SOU EXTENSION 2 FILED Type: EXT2
  • 7/9/2025 - a year ago
    21 - SOU EXTENSION 2 GRANTED Type: EX2G
  • 7/10/2025 - a year ago
    22 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA